AI Proteins

Executive Summary

AI Proteins is a biotechnology company pioneering the design of de novo miniprotein therapeutics using artificial intelligence, robotics, and synthetic biology. Founded in 2021 and based in Cambridge, Massachusetts, the company aims to create a new class of programmable, safer, and more precise biologic medicines from first principles, unconstrained by natural evolution. By leveraging AI-driven protein design and high-throughput screening, AI Proteins seeks to develop miniproteins that can target previously undruggable targets with improved stability, tissue penetration, and manufacturability. The company's approach has the potential to revolutionize drug development by enabling rapid generation of novel therapeutics for a wide range of diseases, including oncology, immunology, and rare genetic disorders. As a private, early-stage company, AI Proteins has not yet disclosed funding rounds or clinical candidates, but its innovative platform positions it as a notable player in the AI-powered drug discovery space.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement70% success
• Q2 2027First Preclinical In Vivo Data Release50% success
• Q1 2027Strategic Partnership with Major Pharma40% success